CureVac N.V. (CVAC)
| Previous Close | 2.9900 |
| Open | 3.0000 |
| Bid | 2.8500 x 100 |
| Ask | 2.8900 x 200 |
| Day's Range | 2.8550 - 3.0000 |
| 52 Week Range | 2.2150 - 12.3600 |
| Volume | |
| Avg. Volume | 775,629 |
| Market Cap | 643.758M |
| Beta (5Y Monthly) | 2.51 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- ACCESSWIRE
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update
Organizational redesign and rightsizing initiated across company to streamline structures, increase efficiency and reduce operating costs Together with GSK, ended Pandemic Preparedness Agreement (PPA) with Federal Republic of Germany, after consultation ...
- ACCESSWIRE
CureVac Appoints Thaminda Ramanayake as New Chief Business Officer
Mr. Ramanayake brings more than fifteen years of experience in biopharma company development and deal-making Strong track record of successful clinical collaborations, M&A, asset in-licensing and strategic financing initiatives across multiple therapeutic ...
- ACCESSWIRE
CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK
Phase 1 part of combined Phase 1/2 study initiated as part of pandemic preparedness against highly pathogenic avian influenza (H5N1) virus, considered to be potential future pandemic threat Study will assess monovalent vaccine candidate, encoding ...
